SG11201401735WA - Tdp-43 specific binding molecules - Google Patents

Tdp-43 specific binding molecules

Info

Publication number
SG11201401735WA
SG11201401735WA SG11201401735WA SG11201401735WA SG11201401735WA SG 11201401735W A SG11201401735W A SG 11201401735WA SG 11201401735W A SG11201401735W A SG 11201401735WA SG 11201401735W A SG11201401735W A SG 11201401735WA SG 11201401735W A SG11201401735W A SG 11201401735WA
Authority
SG
Singapore
Prior art keywords
tdp
specific binding
binding molecules
molecules
specific
Prior art date
Application number
SG11201401735WA
Other languages
English (en)
Inventor
Nitsch Roger
Christoph Hock
Montrasio Maria Grazia Barenco
Fabio Montrasio
Jan Grimm
Jean-Luc Baeriswyl
Paul Weinreb
Janaky Coomaraswamy
Omar Quintero-Monzon
Original Assignee
Biogen Idec Internat Neuroscience Gmbh
Univ Zuerich
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Internat Neuroscience Gmbh, Univ Zuerich filed Critical Biogen Idec Internat Neuroscience Gmbh
Publication of SG11201401735WA publication Critical patent/SG11201401735WA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1018—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Radiology & Medical Imaging (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Optics & Photonics (AREA)
  • Psychology (AREA)
SG11201401735WA 2011-10-28 2012-10-26 Tdp-43 specific binding molecules SG11201401735WA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161553113P 2011-10-28 2011-10-28
PCT/IB2012/002905 WO2013061163A2 (fr) 2011-10-28 2012-10-26 Molécules de liaison spécifiques de tdp-43

Publications (1)

Publication Number Publication Date
SG11201401735WA true SG11201401735WA (en) 2014-05-29

Family

ID=47720540

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201401735WA SG11201401735WA (en) 2011-10-28 2012-10-26 Tdp-43 specific binding molecules

Country Status (18)

Country Link
US (3) US9587014B2 (fr)
EP (2) EP3964524A1 (fr)
JP (3) JP6240611B2 (fr)
KR (2) KR102032080B1 (fr)
CN (1) CN104159918B (fr)
AU (1) AU2012327211C9 (fr)
BR (1) BR112014010161B1 (fr)
CA (2) CA3112082A1 (fr)
CL (1) CL2014001074A1 (fr)
EA (1) EA032003B1 (fr)
ES (1) ES2883212T3 (fr)
HK (1) HK1201846A1 (fr)
IL (2) IL232219B (fr)
MX (2) MX357678B (fr)
MY (1) MY167795A (fr)
SG (1) SG11201401735WA (fr)
WO (1) WO2013061163A2 (fr)
ZA (1) ZA201403680B (fr)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL199534A (en) 2007-01-05 2013-01-31 Univ Zuerich An isolated human antibody capable of detecting a neoepitope in a disease-related protein, a polynucleotide encoding an antibody, a vector containing the polynucleotide, a host cell containing the polynucleotide or vector, a preparation containing the antibody and related methods and uses.
CA3112082A1 (fr) 2011-10-28 2013-05-02 University Of Zurich Molecules de liaison specifiques de tdp-43
EP3008083B1 (fr) 2013-06-11 2021-06-30 Paul Scherrer Institut Procédé de détermination de liaison ligand mutable-gpcr à une résolution d'un seul acide aminé et paires de ligand muté et de gpcr
EP3099712A4 (fr) * 2014-01-31 2017-11-08 Arizona Board of Regents on behalf of Arizona State University Réactifs à base d'anticorps qui reconnaissent spécifiquement les formes de la protéine tdp-43 associées à une maladie neurodégénérative
KR102643395B1 (ko) 2014-07-29 2024-03-11 뉴리뮨 홀딩 아게 인간-유래의 항-헌팅틴(htt) 항체 및 그의 용도
CN104497121A (zh) * 2014-08-29 2015-04-08 苏州顺升桥生物科技有限公司 淀粉样蛋白tdp-43及其用途
TWI592423B (zh) * 2014-10-03 2017-07-21 中央研究院 可辨識致病性ｔｄｐ－４３之抗體及其用途
US9796778B1 (en) 2014-10-03 2017-10-24 Academia Sinica Antibodies against pathological forms of TDP-43 and uses thereof
WO2016053610A1 (fr) * 2014-10-03 2016-04-07 Academia Sinica Anticorps contre les formes pathologiques de tdp-43 et utilisations de ces derniers
MA41115A (fr) 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
WO2017111166A1 (fr) * 2015-12-25 2017-06-29 国立大学法人東京農工大学 Agent thérapeutique pour le traitement d'une maladie liée à la teneur de tdp-43 intracellulaire
DK3430397T3 (da) 2016-03-14 2022-05-02 Biogen Int Neuroscience Gmbh Antistofafhængig cellemedieret fagocytoseassay til pålidelig måling af optagelse af aggregerede proteiner
US20190330318A1 (en) 2016-07-25 2019-10-31 Biogen Ma Inc. Anti-hspa5 (grp78) antibodies and uses thereof
WO2018112362A1 (fr) 2016-12-16 2018-06-21 Biogen Ma Inc. Facteur 11 de différenciation de croissance activé protéolytiquement stabilisé
JP7211961B2 (ja) * 2017-03-14 2023-01-24 ファイヴ プライム セラピューティクス インク 酸性ｐＨでＶＩＳＴＡに結合する抗体
US11214613B2 (en) 2017-05-30 2022-01-04 The University Of British Columbia Epitopes in the RNA recognition motif 1 (RRM1) of TDP-43 and misfolding-selective antibodies thereto
IL272773B2 (en) 2017-08-22 2024-06-01 Biogen Ma Inc Pharmaceutical preparations containing anti-amyloid cell antibodies
WO2019118527A1 (fr) * 2017-12-14 2019-06-20 The Johns Hopkins University Nouveaux inhibiteurs antifongiques
EP3724232A4 (fr) 2017-12-14 2021-12-15 The University of Ottawa Encapsulation d'exosomes et autophagie ciblée
SG11202006348VA (en) 2018-01-05 2020-07-29 Ac Immune Sa Misfolded tdp-43 binding molecules
WO2019177138A1 (fr) 2018-03-16 2019-09-19 国立大学法人滋賀医科大学 Fragment d'anticorps dégradant et éliminant une tdp-43 anormale
TW202019398A (zh) * 2018-06-28 2020-06-01 張翔毓 用於治療或預防構形疾病之方法及藥物篩選方法
CN112638948A (zh) 2018-07-11 2021-04-09 戊瑞治疗有限公司 在酸性pH下结合至VISTA的抗体
MX2021004772A (es) 2018-10-29 2021-08-16 Biogen Ma Inc Variantes de fc5 humanizado y estabilizado para mejorar el transporte de la barrera hematoencefalica.
WO2020118458A1 (fr) * 2018-12-14 2020-06-18 The University Of British Columbia Anticorps anti-tdp-43 mal repliée et méthodes d'utilisation
WO2020234473A1 (fr) * 2019-05-23 2020-11-26 Ac Immune Sa Molécules de liaison anti-tdp-43 et leurs utilisations
EP4013773A4 (fr) * 2019-08-12 2023-08-23 Macquarie University Compositions et méthodes de traitement
GB202004863D0 (en) * 2020-04-02 2020-05-20 Univ Oxford Innovation Ltd Method
EP4143215A2 (fr) 2020-04-28 2023-03-08 SOLA Biosciences LLC Compositions et méthodes pour le traitement de protéinopathies tdp-43
CA3176840A1 (fr) * 2020-04-29 2021-11-04 Neil R. Cashman Anticorps et intracorps a chaine unique a tdp-43 mal repliee et procede d'utilisation
JP2023547580A (ja) * 2020-07-06 2023-11-13 ザ ボード オブ リージェンツ オブ ザ ユニバーシティ オブ テキサス システム Ｔｄｐ－４３バイオセンサー細胞株
JP2023537761A (ja) 2020-08-14 2023-09-05 エイシー イミューン ソシエテ アノニム ヒト化抗ｔｄｐ－４３結合分子およびその使用
CA3203308A1 (fr) 2020-11-30 2022-06-02 Enigma Biointelligence, Inc. Evaluation non invasive de la maladie d'alzheimer
CN112920264B (zh) * 2021-02-08 2022-07-05 武汉大学 Tdp-43蛋白的o-糖基化突变体及其应用
JP6961278B1 (ja) * 2021-03-10 2021-11-05 国立研究開発法人量子科学技術研究開発機構 生体試料中のｔｄｐ−４３を測定する方法及び装置
WO2022251421A1 (fr) * 2021-05-27 2022-12-01 Mayo Foundation For Medical Education And Research Procédés et matériaux pour le traitement de protéinopathies
WO2023056462A1 (fr) * 2021-10-01 2023-04-06 University Of Utah Research Foundation Tdp-43 pathologique utilisé en tant que biomarqueur pour le diagnostic de la protéinopathie tdp-43
WO2023099788A1 (fr) 2021-12-03 2023-06-08 Neurimmune Ag Nouveau dosage de puissance pour des médicaments à base d'anticorps et moyens utiles associés
TW202342519A (zh) 2022-02-16 2023-11-01 瑞士商Ａｃ 免疫有限公司 人源化抗ｔｄｐ－４３結合分子及其用途
WO2023194565A1 (fr) * 2022-04-08 2023-10-12 Ac Immune Sa Molécules de liaison anti-tdp-43
WO2023205579A1 (fr) * 2022-04-18 2023-10-26 The Regents Of The University Of California Compositions et procédés de dislocation d'agrégats pathologiques
WO2024184494A1 (fr) 2023-03-08 2024-09-12 Ac Immune Sa Molécules de liaison anti-tdp-43 et leurs utilisations

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5688511A (en) * 1991-11-05 1997-11-18 Board Of Regents, The University Of Texas System Cellular protein TDP-43 and regulation of HIV-1 gene expression
CA2253633A1 (fr) * 1997-12-03 1999-06-03 Boehringer Mannheim Corporation Anticorps complexes particuliers, methode de preparation et utilisations
US8354236B2 (en) * 2006-09-29 2013-01-15 The Trustees Of The University Of Pennsylvania Detection of neurodegenerative disease
HUE033325T2 (en) * 2007-01-05 2017-11-28 Univ Zuerich Anti-beta-amyloid binder antibodies and their use
WO2008151055A1 (fr) 2007-06-01 2008-12-11 Mayo Foundation For Medical Education And Research Diagnostic de maladies neurodégénératives
JP5439176B2 (ja) * 2007-07-06 2014-03-12 公益財団法人東京都医学総合研究所 Ｔｄｐ−４３凝集物に特異的に結合する抗体
JP5798322B2 (ja) 2008-02-01 2015-10-21 ワシントン ユニバーシティ イン セント ルイス Ｔｄｐ−４３蛋白質症に関連した配列およびその使用法
CN102317316B (zh) 2008-12-19 2014-08-13 帕尼玛制药股份公司 人抗α突触核蛋白自身抗体
CN101634656A (zh) 2009-08-21 2010-01-27 武汉三鹰生物技术有限公司 人tdp-43的单抗包被酶标板的制法及elisa检测试剂盒
CA3112082A1 (fr) 2011-10-28 2013-05-02 University Of Zurich Molecules de liaison specifiques de tdp-43

Also Published As

Publication number Publication date
MX2018008680A (es) 2023-04-18
IL232219B (en) 2019-11-28
WO2013061163A3 (fr) 2014-03-06
CN104159918B (zh) 2019-09-13
KR101961508B1 (ko) 2019-03-25
BR112014010161B1 (pt) 2022-02-08
WO2013061163A2 (fr) 2013-05-02
JP6417451B2 (ja) 2018-11-07
AU2012327211A1 (en) 2013-05-23
HK1201846A1 (en) 2015-09-11
IL270223B (en) 2021-05-31
EP3964524A1 (fr) 2022-03-09
EA032003B1 (ru) 2019-03-29
IL232219A0 (en) 2014-06-30
JP6652609B2 (ja) 2020-02-26
ES2883212T3 (es) 2021-12-07
JP2015505665A (ja) 2015-02-26
JP6240611B2 (ja) 2017-11-29
NZ624871A (en) 2016-06-24
EP2771359A2 (fr) 2014-09-03
JP2019022500A (ja) 2019-02-14
AU2012327211C1 (en) 2016-09-15
CA2853412C (fr) 2021-05-04
MY167795A (en) 2018-09-26
JP2017205118A (ja) 2017-11-24
MX357678B (es) 2018-07-19
KR20180132977A (ko) 2018-12-12
US9587014B2 (en) 2017-03-07
CN104159918A (zh) 2014-11-19
US20140255304A1 (en) 2014-09-11
KR20140100480A (ko) 2014-08-14
KR102032080B1 (ko) 2019-10-15
AU2012327211C9 (en) 2016-11-17
MX2014005048A (es) 2014-11-10
BR112014010161A2 (pt) 2018-09-25
CA3112082A1 (fr) 2013-05-02
US11091540B2 (en) 2021-08-17
EA201490825A1 (ru) 2015-01-30
CA2853412A1 (fr) 2013-05-02
EA201490825A8 (ru) 2016-09-30
US20170152308A1 (en) 2017-06-01
ZA201403680B (en) 2020-05-27
EP2771359B1 (fr) 2021-05-19
AU2012327211B2 (en) 2016-03-10
US10259866B2 (en) 2019-04-16
CL2014001074A1 (es) 2015-01-09
US20200017577A1 (en) 2020-01-16

Similar Documents

Publication Publication Date Title
IL270223B (en) Molecules that specifically bind tdp–43
HRP20181553T1 (hr) Molekule koje se vežu na anti-alfa-sinuklein
IL268336B (en) il-18 binding molecules
HRP20181355T1 (hr) Bispecifične molekule koje se vežu na antigen
HK1247938A1 (zh) 結合分子的生成
IL235134B (en) il–6 binding molecules
EP2793918A4 (fr) Peptides de liaison à hdc-sign
GB201107170D0 (en) Binding molecules with biased recognition
GB201200563D0 (en) Binding molecule
GB201013665D0 (en) Molecules
GB201113890D0 (en) Binding surfaces
GB201103961D0 (en) Binding polypeptides